Shares of Glenmark Pharma Ltd are buying and selling flat after touching a day’s excessive of Rs 2,197.70 on 14th July, following the corporate’s disclosure that it acquired a warning letter from the US Meals and Drug Administration (USFDA) for its facility in Indore, Madhya Pradesh, in line with an alternate submitting yesterday.
The USFDA inspected Glenmark Pharma’s Indore facility between third and 14th February, 2025. Later, it was given an Official Motion Indicated (OAI) standing in Might 2025. The warning letter adopted this inspection.
The corporate clarified that no knowledge integrity points have been discovered. Moreover, the letter is just not anticipated to have an effect on present revenues or disrupt provides from the power.
Glenmark has acquired related warning letters previously. One was for its Monroe facility in 2023, which was later re-inspected in June 2025. One other was for its Goa facility in November 2022.
A warning letter from the USFDA is a severe discover, normally indicating non-compliance that might pose dangers to public well being.
Glenmark said that it stays dedicated to high quality and CGMP compliance throughout all its manufacturing websites.
Individually, final week, Glenmark’s unit Ichnos Glenmark Innovation (IGI) signed a licensing take care of AbbVie for its experimental most cancers drug ISB 2001. This drug is at the moment in Part 1B trials for a number of myeloma. AbbVie will deal with growth and gross sales in main markets. In the meantime, Glenmark will retain rights in India and rising markets.
At 11:13 AM, the shares of Glenmark Pharma have been buying and selling 0.68% decrease at Rs 2,166.30 on NSE.
Curious About Glenmark Pharma? Ask the Analyst.
Unicorn Alerts leverages superior AI know-how to offer you highly effective market predictions and actionable inventory scans. Obtain the app immediately and 10x your buying and selling & investing journey!
